TCGA-78-7537-01A-11R-2066-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.320
- ANGIOGENESIS+0.290
- HEDGEHOG_SIGNALING+0.250
- COAGULATION+0.210
- MYOGENESIS+0.210
- FATTY_ACID_METABOLISM+0.200
- ADIPOGENESIS+0.180
- ESTROGEN_RESPONSE_EARLY+0.170
- HEME_METABOLISM+0.160
- OXIDATIVE_PHOSPHORYLATION+0.150
Top 10 suppressed
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.650
- MYC_TARGETS_V2-0.560
- MYC_TARGETS_V1-0.500
- MTORC1_SIGNALING-0.430
- MITOTIC_SPINDLE-0.420
- INTERFERON_GAMMA_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- INTERFERON_ALPHA_RESPONSE-0.310
- HYPOXIA-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.853 |
| 2 | TCGA-49-4510-01A-01R-1206-07 | — | cohortA2 | 0.842 |
| 3 | SRR25617843 | — | B | 0.841 |
| 4 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.838 |
| 5 | 6a2c6371-d8c6-4ca0-9a25-da16ed281d60 | — | — | 0.830 |
| 6 | sclcCHTN02019_S70.txt | — | cohortSC | 0.829 |
| 7 | C3L-02165 | — | cohortA2 | 0.826 |
| 8 | C3L-03463 | — | cohortA3 | 0.825 |
| 9 | TCGA-62-A46P-01A-11R-A24H-07 | — | cohortA3 | 0.813 |
| 10 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |